Advances in the gene-editing technology known as CRISPR-Cas9 over the past 15 years have yielded important new insights into the roles that specific genes play in many diseases. But to date this ...
Deal includes $1 billion upfront, $300 million for clinical milestones Verve shares surge 75% in early trading Analysts view acquisition as positive for gene-editing sector The companies were ...
Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback